(Q43049225)

12 November 2017

title

Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C. (English)

1 reference

12 November 2017

1 reference

Cheng PN

1

1 reference

12 November 2017

Chow NH

2

1 reference

12 November 2017

Hu SC

3

1 reference

12 November 2017

Young KC

4

1 reference

12 November 2017

Chen CY

5

1 reference

12 November 2017

Jen CM

6

1 reference

12 November 2017

Chang TT

7

1 reference

12 November 2017

publication date

1 December 2002

1 reference

Digestive and Liver Disease

12 November 2017

published in

1 reference

12 November 2017

volume

34

1 reference

12 November 2017

issue

12

1 reference

12 November 2017

page(s)

851-856

1 reference

Clinical outcomes after transfusion-associated hepatitis C.

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Human leucocyte interferon-alpha in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Molecular mechanisms of action of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Re-treatment with interferon alfa of patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Efficacy of interferon monotherapy in the treatment of relapsers and nonresponders with chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-alpha therapy in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980255-9

7 January 2021

10.1016/S1590-8658(02)80255-9

Identifiers

DOI

1 reference

12 November 2017

1 reference